171 related articles for article (PubMed ID: 20055754)
1. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis.
Kawata K; Kobayashi Y; Souda K; Kawamura K; Sumiyoshi S; Takahashi Y; Noritake H; Watanabe S; Suehiro T; Nakamura H
Antioxid Redox Signal; 2010 Aug; 13(3):259-68. PubMed ID: 20055754
[TBL] [Abstract][Full Text] [Related]
2. Does hepatic oxidative stress enhance activation of nuclear factor-E2-related factor in patients with nonalcoholic steatohepatitis?
Takahashi Y; Kobayashi Y; Kawata K; Kawamura K; Sumiyoshi S; Noritake H; Watanabe S; Chida T; Souda K; Sakaguchi T; Nakamura H; Suda T
Antioxid Redox Signal; 2014 Jan; 20(3):538-43. PubMed ID: 23822105
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
4. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice.
Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Takeda K; Utsunomiya H; Oda K; Warabi E; Ishii T; Osaka K; Hyodo I; Yamamoto M
Am J Physiol Gastrointest Liver Physiol; 2008 Oct; 295(4):G735-47. PubMed ID: 18687751
[TBL] [Abstract][Full Text] [Related]
6. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants.
Mitsuyoshi H; Nakashima T; Sumida Y; Yoh T; Nakajima Y; Ishikawa H; Inaba K; Sakamoto Y; Okanoue T; Kashima K
Biochem Biophys Res Commun; 1999 Sep; 263(2):537-42. PubMed ID: 10491327
[TBL] [Abstract][Full Text] [Related]
9. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid treatment in a patient with primary biliary cirrhosis.
Wouters RS; Bos LP; Engels LG
Neth J Med; 1990 Aug; 37(1-2):21-3. PubMed ID: 2215828
[TBL] [Abstract][Full Text] [Related]
11. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
[TBL] [Abstract][Full Text] [Related]
12. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
16. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
18. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
19. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
20. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
